Summer 2025

Software Engineer Intern

Posted on 2/25/2025

Elsevier

Elsevier

10,001+ employees

Global STM publisher of journals.

Compensation Overview

$28 - $30/hr

Company Does Not Provide H1B Sponsorship

Pennsylvania, USA + 3 more

More locations: Florida, USA | New York, NY, USA | Massachusetts, USA

The job is open to candidates in the eastern and central time zones.

The job is open to candidates in the eastern and central time zones.

The job is open to candidates in the eastern and central time zones.

Category
Software Engineering (1)
Required Skills
Agile
Git
Java
Postgres
AWS
JIRA
SCRUM
Oracle

Get referred to Elsevier

Find people who can refer or advise you

Requirements
  • Be a current student pursuing a bachelor's or masters in a related field (i.e., Computer Science, Computer Engineering, etc.) and graduating May 2026 or later.
  • Possess hands-on development experience with Java and AWS.
  • Demonstrate a working knowledge of relational databases such as Oracle, AWS, RDS, or PostgreSQL.
  • Thrive on working collaboratively and enjoy supporting, learning from, and sharing knowledge with a team of people from different backgrounds.
  • Familiarity and experience with unit or integration tests for your code are advantageous.
  • Familiarity with Agile/Scrum methodology using Jira is advantageous.
  • Familiarity with source control management systems such as GitHub is advantageous.
Responsibilities
  • Working to learn the relevant technologies and systems in place.
  • Completing clearly defined tasks and effectively communicating when something is blocking progress.
  • Making an impact by delivering features, refactoring existing code, and actively maintaining and extending our current systems.
  • Working closely with other developers and stakeholders to learn and understand our goals and workflows, your tasks, and our agile-based development approach.
  • Helping debug technical problems and submitting issues so that we can document and improve our services.
  • Demonstrating solid engineering fundamentals, have a good work ethic, and be able to communicate clearly and in a respectful manner.

Elsevier provides scientific, medical, and technical content and analytics to researchers, educators, clinicians, and institutions worldwide through journals, books, databases, and digital platforms. It operates by offering access to peer-reviewed articles and professional literature via online platforms, along with tools for discovery, citation tracking, research management, and clinical decision support. Unlike other publishers, Elsevier combines a broad portfolio of STM content with integrated analytics and workflow tools, serving researchers, healthcare professionals, and academic institutions on a global scale. Its goal is to enable the advancement of knowledge and improve health outcomes by delivering reliable, accessible information and data-driven solutions across the research lifecycle.

Company Size

10,001+

Company Stage

N/A

Total Funding

N/A

Headquarters

Amsterdam, Netherlands

Founded

1880

Get referred to Elsevier

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • LeapSpace AI saved 97% of users time, with over half saving more than 50% of research time.
  • Wellsheet acquisition enables ClinicalKey AI to surface trusted clinical evidence directly in EHRs across 139 US hospital sites.
  • StudyFinder AI launched June 2026 connects medical students to curriculum-aligned, NICE-guideline-backed content, addressing unverified AI use by 74% of students.

What critics are saying

  • CzechELib’s July 2026 OA agreement erodes APC revenue by 10–15% per Czech article, with 20+ similar deals likely in 2026–2027.
  • CAUL contract failure starting January 2026 cuts access to 1,659 journals for 30+ Australasian universities, triggering 15–25% subscription renewal drops.
  • EU’s 2027 Article 13 OA mandate could eliminate Elsevier’s hybrid model, forcing 30–40% cost restructuring with existential impact.

What makes Elsevier unique

  • Elsevier owns 20M+ peer-reviewed articles and 100M Scopus records, enabling trusted AI like LeapSpace and ClinicalKey AI.
  • Its patented AI Conversation Engine in Shadow Health Lab enables natural-language patient simulations for nursing students.
  • ClinicalKey AI integrates with 1,000 journals and 300+ hospitals, delivering verifiable, patient-specific guidance inside EHR workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Employee Assistance Program

Short-and-Long Term Disability

Life Insurance

Accidental Death Insurance

Wellness Program

Family Planning Benefits

Fertility Treatment Support

Health Savings Account/Flexible Spending Account

Company News

Sardon Lab
Jun 15th, 2026
8th International Symposium Frontiers in Polymer Science.

8th International Symposium Frontiers in Polymer Science. Prof. Haritz Sardon and Dr. Xabi Lopez de Pariza recently participated in the Elsevier event, the Eighth International Symposium Frontiers in Polymer Science, held in Chengdu, China, from 11 to 14 June 2026. Haritz Sardon Lab is delighted to announce that both researchers received prestigious recognition for their outstanding contributions. Prof. Sardon was awarded for his invited lecture, From Recycling Legacy Plastics to Designing Functional Plastics with Circularity, presented on Friday, 12 June. Dr. Lopez de Priza received the Best Poster Award for his presentation entitled Standardizing Light: A Modular Photoreactor for Controlled, Reproducible and High-Throughput Photochemical Reactions. Congratulations to both on these well-deserved achievements, and Haritz Sardon Lab wish them continued success in their research endeavors!

Open Exploration Publishing
Jun 5th, 2026
2025 CiteScore Released: Open Exploration Journals Reach New Heights in Academic Impact

2025 CiteScore released: Open Exploration journals reach new heights in academic impact. Jun. 5, 2026 683 On June 3, 2026, Elsevier officially released the 2025 CiteScore data. As one of the core metrics for measuring journal academic impact in the international academic community, the annual update of CiteScore objectively reflects the academic dissemination capability and disciplinary development level of journals in recent years. This year, a total of 5 Open Exploration journals indexed in Scopus have demonstrated outstanding performance, with multiple indicators showing upward trends. Among them, Exploration of Medicine (EM) and Exploration of Targeted Anti-tumor Therapy (ETAT) both ranked in the Q2 quartile in their respective disciplines. EM has achieved significant improvements in both score and ranking, while ETAT has entered the Q2 quartile in oncology for the first time, achieving an annual increase of 74.19% in its score, rising to 5.4. Exploration of Immunology (EI) and Exploration of Neuroprotective Therapy (ENT) have both maintained consecutive year-over-year growth, demonstrating their development potential in their respective fields. The newly indexed journal Exploration of Foods and Foodomics (EFF) has received its first CiteScore of 2.4, marking a significant milestone. Below is the detailed information of the CiteScores for 5 journals. Exploration of Medicine (EM) The 2025 CiteScore of Exploration of Medicine rose to 2.9, a year-on-year increase of 61.11% from 1.8 in 2024, maintaining its Q2 position in General Medicine. Ranked 207th among 669 journals in the field, EM climbed 60 places compared to the previous year, reflecting substantial improvements in citation levels and overall academic quality. The journal focuses on innovative clinical and basic medical research in general medicine and is now indexed in authoritative databases including Scopus, Google Scholar, DOAJ, and CAS. Welcome to submit at: https://em.aressystem.com/. Exploration of Targeted Anti-tumor Therapy (ETAT) The 2025 CiteScore of Exploration of Targeted Anti-tumor Therapy reached 5.4, an impressive 74.19% increase from the previous year. For the first time, ETAT entered the Q2 quartile in Oncology, ranking 140th among 428 journals in the field - a breakthrough development. The journal focuses on frontiers of targeted therapy and clinical translational research, and is indexed in Scopus, PubMed/PMC, Google Scholar, and other authoritative databases. ETAT's CiteScore has maintained continuous growth for four consecutive years (1.7 in 2022 | 2.8 in 2023 | 3.1 in 2024 | 5.4 in 2025), steadily enhancing its academic influence with sustained support from its editorial board, reviewers, and authors. Welcome to submit at: https://etat.aressystem.com. Exploration of Immunology (EI) The 2025 CiteScore of Exploration of Immunology increased to 1.9, achieving consecutive annual growth (1.0 in 2023 | 1.5 in 2024 | 1.9 in 2025). This upward trend indicates continuous improvement in the journal's academic quality and reader engagement, highlighting its development potential in the field of immunology. EI focuses on fundamental immunology and mechanisms of immune diseases, publishing high-quality academic outputs, and is indexed in Scopus, Google Scholar, DOAJ, CAS, and other major databases. Welcome to submit at: https://ei.aressystem.com. Exploration of Neuroprotective Therapy (ENT) The 2025 CiteScore of Exploration of Neuroprotective Therapy rose to 2.6, a 30% increase from 2.0 in 2024. ENT specializes in neurodegenerative diseases, neuroprotection, and neurorestoration, with a precise academic focus and rigorous review standards. Indexed in Scopus, Google Scholar, DOAJ, CAS, and other mainstream databases, ENT's academic influence in neuroscience continues to grow steadily. The journal will remain committed to publishing cutting-edge research in neuroprotection and providing a high-quality communication platform for scholars. Welcome to submit at: https://ent.aressystem.com. Exploration of Foods and Foodomics (EFF) Exploration of Foods and Foodomics was indexed in Scopus in June 2025 and received its first-ever CiteScore of 2.4 in this release - a solid foundation for future growth. This milestone recognizes the journal's publication quality, topic value, and academic standards, which have been acknowledged by an internationally authoritative platform. EFF focuses on the interdisciplinary frontiers of food science and foodomics, contributing to academic innovation and translational outcomes in the food field. It is currently indexed in Scopus, Google Scholar, DOAJ, CAS, and other major databases, with its international academic influence steadily rising. Welcome to submit at: https://eff.aressystem.com. About the 2025 CiteScore The CiteScore metric is calculated by dividing the total citations received by all documents published in a journal over a four-year period (including research articles, review articles, conference papers, data papers, and book chapters) by the total number of such documents published during the same period. The 2025 CiteScore covers the citation window from 2022 to 2025. As an important reference for measuring journal academic impact, CiteScore provides an intuitive reflection of a journal's sustained academic contribution and literature dissemination efficiency, while also offering an objective basis for scholars to select journals for submission, track disciplinary hotspots, and evaluate the academic value of research outputs. Advancing Scholarship, Embracing the Future The achievements of Open Exploration journals in this year's CiteScore release would not have been possible without the professional support and collective efforts of the editorial board members, peer reviewers, and author community. Moving forward, Open Exploration will continue to uphold rigorous peer review mechanisms, adhere to principles of academic integrity in publishing, further optimize manuscript processing workflows, and enhance the author service experience. Open Exploration Publishing Inc. remain committed to publishing high-quality academic achievements, continuously improving its publishing standards and international academic influence. Open Exploration looks forward to collaborating with more researchers to promote the broad dissemination and sharing of academic achievements.

myGwork
Apr 10th, 2026
Elsevier has been recognized among India's top 50 best workplaces(tm) in health & wellness 2026: companies that care by great place to work(r).

Elsevier has been recognized among India's top 50 best workplaces(tm) in health & wellness 2026: companies that care by great place to work(r). April 10, 2026 We're pleased to share that Elsevier has been recognized among India's top 50 best workplaces(tm) in health & wellness 2026: companies that care by great place to work(r). This recognition is based on insights from over 170,000 employees across 260+ organizations in India, and it reinforces something we deeply believe, when people feel supported, they do their best work. At Elsevier, we remain committed to creating a workplace where wellbeing is prioritized. A big thank you to our people who make this wellness and well-being culture possible every day.

The Colorado Sun
Mar 31st, 2026
Colorado SunFest 2026 panel: exploring 150 years of statehood.

Colorado SunFest 2026 panel: exploring 150 years of statehood. History Colorado will join Colorado SunFest 2026 to discuss the state's history and how it's been told and shaped The Colorado Sun 9:22 AM MDT on Mar 31, 2026Updated 4:52 PM MDT on Apr 2, 2026 Colorado SunFest 2026 is a daylong event bringing Coloradans together to discuss what makes A Better Colorado. Find out more about specific sessions planned for Friday, May 1, below. Panel Name: Colorado Turns 150 On Aug. 1, Colorado will mark its 150th year of statehood, and to celebrate, The Colorado Sun is working on a series called Colorado 150, a curated list of 150 things that make the state colorful. The conversation, as part of the celebration, will look into the state's history and how it's been told and shaped. While Colorado is working to broaden its history, the federal government is working to narrow it. Panelists Jason Hanson, chief creative officer and director of interpretation & research at History Colorado, and Annie Levinsky, vice president of History Colorado, will explore Colorado's history and the current "heritage audit" going on at History Colorado. Jason Hanson, chief creative officer and director of interpretation & research at History Colorado. Hanson has worked for History Colorado since 2016, serving as the chief creative officer of interpretation and research, as well as the deputy state historian. In his role, he works closely with the Colorado State Historian's Council as the deputy state historian, and is a member of the state's American 250-Colorado 150 Commission. Previously, Hanson has served as research faculty for the University of Colorado's Center of the American West in Boulder, and a production editor for Elsevier Publishing. His most recent book, "Brewed at Altitude: A Beer Lover's History of Colorado," with Sam Bock, was recently published to mark 150 years as the Centennial State. He received his Master of Arts in City/Urban, Community and Regional Planning from the University of Colorado-Denver and his Master of Arts in History from the University of Colorado-Boulder. Annie Levinsky, vice president of History Colorado. Levinsky is leading the Heritage for All project, a part of the Colorado 150th celebration and the country's 250th celebration, the project aims to change the way community preservation is viewed. Previously, she served as executive director for Historic Denver, Inc. for more than 12 years, and worked at the Molly Brown House Museum, located in Denver and owned by Historic Denver - for more than six years. Levinsky received her degree from Colorado College. The panel, "Colorado turns 150" is one of 11 conversations scheduled for Colorado SunFest 2026. The fourth annual Colorado SunFest is Friday, May 1, at Josef Korbel School of Global and Public Affairs on the University of Denver campus. Tickets for the event are available on The Colorado SunFest event page. Other Colorado SunFest sessions. Type of story: behind the story. Clarifies for the public how a story was reported.

Mednext Healthcare
Mar 24th, 2026
NCPDP appoints Julia Vu, PharmD, as EVP of Public Policy and Professional Relations.

NCPDP appoints Julia Vu, PharmD, as EVP of Public Policy and Professional Relations. Up next. Published on 24 March 2026 New leadership role aims to enhance healthcare policy initiatives. * Julia Vu joins NCPDP as Executive Vice President. * Focused on advancing healthcare policy initiatives. * Experience includes previous leadership role at Elsevier. The National Council for Prescription Drug Programs (NCPDP) has appointed Julia Vu, PharmD, as the new Executive Vice President of Public Policy and Professional Relations. In this role, Vu will focus on advancing healthcare policies and initiatives while enhancing the organization's influence within the industry. Her extensive background in the healthcare sector positions her to address the evolving landscape of pharmacy services and medication management. Before joining NCPDP, Vu served as Vice President at Elsevier, where she led various strategic initiatives relevant to healthcare delivery and medication optimization. Her experience in public policy and pharmacy practice will support NCPDP's mission to improve health outcomes through effective advocacy and stakeholder engagement. This appointment comes at a crucial time as NCPDP continues to adapt to new challenges and opportunities in the healthcare system. Vu's experience also includes time spent in regulatory affairs and stakeholder collaboration, which will be instrumental as NCPDP engages with diverse healthcare professionals and policy-makers. As the organization looks to strengthen its role in the healthcare industry, Vu's leadership is expected to bring a fresh perspective to the ongoing dialogue on critical pharmacy and medication-related issues. You may also like. Services PMI at 53.8 in january 2026, according to ISM report. January sees strong growth in services sector as PMI remains robust. Services... * February 4, 2026 Pharmacelera raises $6M to expand in US and enhance drug discovery platform. Funding will support growth and technological advancements in drug discovery. Pharmacelera has... * February 18, 2026 BD helps scientists advance immunology and cancer research with ai-powered insights and automation. Innovative automation enhances cancer research and immunological studies. AI-powered tools improve research... NUNM receives $1.5 million gift to support campus expansion and future integrative medicine center. Major donation aims to enhance educational opportunities at NUNM. NUNM receives a... * February 28, 2026

INACTIVE